title: Nasal nitric oxide is associated with exhaled NO, bronchial responsiveness and poor asthma control.
abstract: The fraction of exhaled nitric oxide (FeNO) is an established marker of airway inflammation in asthma. Nasal nitric oxide (nNO) has initially been regarded as a promising marker of inflammation of nasal mucosa. However, due to its dual origins, paranasal sinuses and nasal mucosa, the clinical use of nNO is controversial. There is an inflammatory link between inflammation in the upper and lower airways within the united airways' paradigm, but the study of the clinical value of nNO in asthma has been limited. The objective of this study is to analyse nNO in asthmatics and its relationship to FeNO, bronchial hyperresponsiveness, allergic sensitization and asthma control. A total of 371 children and young adults from an asthma cohort were included in this study, which performed measurements of nNO (through aspiration at 5 mL s(-1)), FeNO, bronchial responsiveness to methacholine, blood eosinophil count (B-Eos) and IgE sensitization. The asthma control test (ACT) and a questionnaire regarding medical treatment, symptoms of asthma, rhinitis and chronic rhinosinusitis were completed by all subjects. An association was found between higher nNO levels and increased bronchial responsiveness (p < 0.001), FeNO (p < 0.001) and B-Eos (p = 0.002). Sensitization to furry animals related to higher levels of nNO (p < 0.001). Subjects with poorly controlled asthma (ACT < 15) had lower levels of nNO than subjects with a higher ACT score (619 ± 278 ppb, versus 807 ± 274 ppb, p = 0.002). Loss of smell showed the strongest association with lower nNO levels among the upper airway symptoms recorded. In patients with asthma, nNO was positively correlated with exhaled NO, bronchial responsiveness and asthma control. This study suggests clinical utility of nNO in subjects with asthma, but in order to get better understanding of the nNO determinants, simultaneous mapping of upper airway comorbidities by clinical examination is appropriate.
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Krantz
authors.forename: C
authors.initials: C
authors.lastname: Janson
authors.forename: M P
authors.initials: MP
authors.lastname: Borres
authors.forename: L
authors.initials: L
authors.lastname: Nordvall
authors.forename: K
authors.initials: K
authors.lastname: Alving
authors.forename: A
authors.initials: A
authors.lastname: Malinovschi
mesh_terms: D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000097:blood / Q000175:diagnosis* / Q000276:immunology / Q000503:physiopathology*; D001980:Bronchi / Q000503:physiopathology*; D002648:Child; D003710:Demography; D045853:Exhalation; D005260:Female; D006801:Humans; D007114:Immunization; D007073:Immunoglobulin E / Q000276:immunology; D007958:Leukocyte Count; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism*; D009569:Nitric Oxide / Q000032:analysis*; D012220:Rhinitis / Q000150:complications; D012907:Smoking / Q000009:adverse effects; D055815:Young Adult
chemical_list: D000485:Allergens; D009569:Nitric Oxide; D007073:Immunoglobulin E